Halozyme slides on an early futility failure for its lead cancer therapy
Halozyme shares slipped 8% on Thursday after the biotech reported that one of its combo studies using PEGPH20 couldn’t clear an early test for futility.
Investigators were using a combination of PEGPH20 plus Folfirinox against Folfirinox alone on previously untreated metastatic pancreatic cancer, a tough challenge for any drug. Now the San Diego-based biotech has halted enrollment as it analyses the data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.